The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer

Papers of special note have been highlighted as: ▪▪ of considerable interest

References

• 1  Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can. J. Urol.15(1),3866–3871 (2008).
  MedlineGoogle Scholar
• 2  Ross RK, Bernstein L, Lobo RA et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet339(8798),887–889 (1992).
  Medline CASGoogle Scholar
• 3  Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med.317(15),909–916 (1987).
  Medline CASGoogle Scholar
• 4  Constantinou J, Feneley MR. PSA testing: an evolving relationship with prostate cancer screening. Prostate Cancer Prostatic Dis.9(1),6–13 (2006).
  Medline CASGoogle Scholar
• 5  Etzioni R, Feuer E. Studies of prostate-cancer mortality: caution advised. Lancet Oncol.9(5),407–409 (2008).
  MedlineGoogle Scholar
• 6  Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J. Clin. Oncol.23(25),6139–6148 (2005).
  MedlineGoogle Scholar
• 7  Scher HI, Warren M, Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin. Cancer Res.13(5),1488–1492 (2007).
  Medline CASGoogle Scholar
• 8  Leman ES, Getzenberg RH. Biomarkers for prostate cancer. J. Cell. Biochem.108(1),3–9 (2009).
  Medline CASGoogle Scholar
• 9  Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per mililiter. N. Engl. J. Med.350(22),2239–2246 (2004); erratum: 351(14),1470 (2004).
  Medline CASGoogle Scholar
• 10  Bunting PS. A guide to the interpretation of serum prostate specific antigen levels. Clin. Biochem.28(3),221–241 (1995).
  Medline CASGoogle Scholar
• 11  Loeb S, Cataona WJ. Prostate-specific antigen in clinical practice. Cancer Lett.249(1),30–39 (2007).
  Medline CASGoogle Scholar
• 12  Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA267(16),2215–2220 (1992).
  Medline CASGoogle Scholar
• 13  Lembessis P, Msaouel P, Halapas A et al. Combined androgen therapy blockade can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clin. Chem. Lab. Med.45(11),1488–1494 (2007).
  Medline CASGoogle Scholar
• 14  Saad F, Perez J, Cook R, Segal S. Evaluation of prostate-specific antigen kinetics during zoledronic acid therapy for bone metastases in patients with castration-resistant prostate cancer. Presented at: AUA Annual Meeting. Washington DC, USA, 14–19 May 2011 (Abstract 717).
  Google Scholar
• 15  Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol.31(5),578–583 (2000).
  Medline CASGoogle Scholar
• 16  Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br. J. Cancer88(2),195–201 (2003).
  Medline CASGoogle Scholar
• 17  Parker C. Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer: a Phase III randomized trial (ALSYMPCA). Presented at: ECCO-ESMO. Stockholm, Sweden, 23–27 September 2011 (Abstract 1LBA).
  Google Scholar
• 18  Smith MR, Egerdie B, Hernandez N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med.361(8),745–755 (2009).
  Medline CASGoogle Scholar
• 19  Ryan CJ, Shah S, Efstathiou E et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin. Cancer Res.17(14),4854–4861 (2011).
  Medline CASGoogle Scholar
• 20  Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin. Prostate Cancer4(1),31–37 (2005).
  Medline CASGoogle Scholar
• 21  Smith MR, Kabbinavar F, Saad F et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J. Clin. Oncol.23(13),2918–2925 (2005).
  MedlineGoogle Scholar
• 22  Sutcliffe P, Hummel S, Simpson E et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol. Assess.15(5),iii, xi–xiii 1–219 (2009).
  Google Scholar
• 23  Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol.23(22),4925–4935 (2005).
  Medline CASGoogle Scholar
• 24  Cook RJ, Coleman R, Brown J et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin. Cancer Res.12(11 Pt 1),3361–3367 (2006).
  Medline CASGoogle Scholar
• 25  Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer110(8),1860–1867 (2007).
  MedlineGoogle Scholar
• 26  Coleman RE. Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat. Rev.27(3),165–176 (2001).
  Medline CASGoogle Scholar
• 27  Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol.16(4),579–584 (2005).
  Medline CASGoogle Scholar
• 28  Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer88(Suppl. 12),2919–2926 (2000).
  Medline CASGoogle Scholar
• 29  Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol. Cancer Ther.6(10),2609–2617 (2007).
  Medline CASGoogle Scholar
• 30  Thayer S, Cooke J, Kaura S. A retrospective database analysis to assess the impact of zoledronic acid (ZOL) on skeletal-related events (SREs) in solid tumor cancer and multiple myeloma (MM) patients (pts). Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009 (Abstract 9518).
  Google Scholar
• 31  Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst.96(11),879–882 (2004).
  Medline CASGoogle Scholar
• 32  Coleman RE. Skeletal complications of malignancy. Cancer80(8 Suppl.),1588–1594 (1997).
  Medline CASGoogle Scholar
• 33  Fizazi K, Carducci MA, Smith MR et al. A randomized Phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J. Clin. Oncol.28(Suppl. 18), Abstract LBA4507 (2010).
  Google Scholar
• 34  Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol. Med.16(9),398–406 (2010).▪▪ Proposes that detection and characterization of circulating tumor cells (CTCs) may provide both prognostic and predictive information that could aid physicians in identifying risk of disease progression and visceral metastases to better guide treatment decisions for patients with castration-resistant prostate cancer (CRPC).
  MedlineGoogle Scholar
• 35  Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J.14,146 (1869).
  Google Scholar
• 36  Hugo H, Ackland ML, Blick T et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J. Cell. Physiol.213(2),374–383 (2007).
  Medline CASGoogle Scholar
• 37  Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat. Rev. Cancer2(6),442–454 (2002).
  Medline CASGoogle Scholar
• 38  Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer3(1),55–63 (2003).
  Medline CASGoogle Scholar
• 39  Lafrenie R, Shaughnessy SG, Orr FW. Cancer cell interactions with injured or activated endothelium. Cancer Metastasis Rev.11(3–4),377–388 (1992).
  Medline CASGoogle Scholar
• 40  Riethdorf S, Fritsche H, Muller V et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res.13(3),920–928 (2007).
  Medline CASGoogle Scholar
• 41  Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating tumor cells: evolving evidence and future challenges. Oncologist14(11),1070–1082 (2009).
  MedlineGoogle Scholar
• 42  Stott SL, Lee RJ, Nagrath S et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci. Transl Med.2(25),25ra23 (2010).
  MedlineGoogle Scholar
• 43  Pelkey TJ, Frierson HF Jr, Bruns DE. Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Clin. Chem.42(9),1369–1381 (1996).
  Medline CASGoogle Scholar
• 44  Davis JW, Nakanishi H, Kumar V et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J. Urol.179(6),2187–2191 (2008).
  MedlineGoogle Scholar
• 45  Kollerman J, Weikert S, Schostak M et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J. Clin. Oncol.26(30),4928–4933 (2008).
  MedlineGoogle Scholar
• 46  Weckermann D, Polzer B, Ragg T et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J. Clin. Oncol.27(10),1549–1556 (2009).
  MedlineGoogle Scholar
• 47  Alix-Panabieres C, Vendrell JP, Pelle O et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin. Chem.53(3),537–539 (2007).
  Medline CASGoogle Scholar
• 48  Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res.10(20),6897–6904 (2004).
  MedlineGoogle Scholar
• 49  Mani SA, Guo W, Liao MJ et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell133(4),704–715 (2008).
  Medline CASGoogle Scholar
• 50  Alix-Panabieres C, Schwarzenback H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu. Rev. Med.63,199–215 (2012).
  Medline CASGoogle Scholar
• 51  Eschwege P, Moutereau S, Droupy S et al. Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study. Br. J. Cancer100(4),608–610 (2009).
  Medline CASGoogle Scholar
• 52  de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res.14(19),6302–6309 (2008).▪▪ This prospective study of 231 patients with CRPC and a prostate-specific antigen level of ≥5 ng/ml was designed to evaluate the relationship between post-treatment CTCs and overall survival (OS). CTC counts predicted OS better than prostate-specific antigen decrement algorithms at all time points. Ultimately, this study led to the US FDA approval of the CellSearch® System for the evaluation of CRPC.
  Medline CASGoogle Scholar
• 53  Scher HI, Jia X, de Bono JS et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol.10(3),233–239 (2009).
  Medline CASGoogle Scholar
• 54  Olmos D, Arkenau HT, Ang JE et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann. Oncol.20(1),27–33 (2009).▪▪ In this study of 119 patients with CRPC, higher CTC counts were associated with baseline characteristics of aggressive disease. Patients with baseline CTCs ≥5 had significantly shorter median OS than those patients with CTCs <5 (19.5 vs >30 months; p < 0.012) and patients with CTCs >50 had significantly shorter median OS than those with CTCs 5–50 (6.3 vs 21.1 months; p < 0.001).
  Medline CASGoogle Scholar
• 55  Danila DC, Heller G, Gignac GA et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res.13(23),7053–7058 (2007).▪▪ Study of 120 patients with progressive CRPC evaluating the association between CTC number, clinical characteristics and survival. Higher CTC counts were observed in patients with bone metastases, as compared with patients with soft tissue disease. The authors concluded that CTCs are an intrinsic property of the tumor, distinct from extent of disease and may provide unique information relative to prognosis.
  Medline CASGoogle Scholar
• 56  Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol.28(9),1489–1495 (2010).
  Medline CASGoogle Scholar
• 57  Scher HI, Heller G, Molina A et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis of COU-AA-301, a randomized double-blind, placebo-controlled Phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J. Clin. Oncol.29(Suppl.), Abstract LBA4517 (2011).▪▪ CTC testing in a Phase III trial of 1195 patients with metastatic CRPC who received abiraterone acetate and low-dose prednisone following docetaxel. As part of a biomarker panel, CTCs demonstrated surrogacy for OS by correlating with survival. Baseline CTCs and CTC conversion were both key predictors of OS.
  Google Scholar
• 58  Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, Phase 2 trial. Lancet Oncol.11(5),421–428 (2010).
  Medline CASGoogle Scholar
• 59  Saad F, Eastham J. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology76(5),1175–1181 (2010).▪▪ Illustrates that early treatment of bone metastases in CRPC patients is especially effective at preventing resulting skeletal-related events, elevating the importance of early identification of bone metastases and evaluation of skeletal-related event and survival risk factors in patients with CRPC.
  MedlineGoogle Scholar
• 60  Kraan J, Sleijfer S, Strijbos MH et al. External quality assurance of circulating tumor cell enumeration using the CellSearch^® system: a feasibility study. Cytometry B Clin. Cytom.80(2),112–118 (2011).
  MedlineGoogle Scholar
• 61  Doyen J, Alix-Panabieres C, Hofman P et al. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. Crit. Rev. Oncol. Hematol.81(3),241–256 (2011) (Epub ahead of print).
  MedlineGoogle Scholar
• 101  GLOBOCAN. Age standardized incidence rates for prostate cancer (2008). http://globocan.iarc.fr/factsheets/cancers/prostate.asp
  Google Scholar
• 102  US FDA. FDA public workshop on clinical trial endpoints in prostate cancer (2004). www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/CancerDrugs/ucm095039.pdf
  Google Scholar